抗パーキンソン病薬

関: antiparkinson agent、antiparkinsonian、antiparkinsonian agent、antiparkinsonian drug

WordNet

use recreational drugs (同)do drugs
administer a drug to; "They drugged the kidnapped tourist" (同)dose
a substance that is used as a medicine or narcotic

PrepTutorEJDIC

『薬』,薬品,薬剤 / 『麻薬』,麻酔剤 / 〈人〉‘に'薬(特に麻酔剤)を与える / 〈飲食物〉‘に'(麻酔薬・毒薬などの)薬を混ぜる

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/08/22 12:31:58」(JST)

wiki en

[Wiki en表示]

An antiparkinson, or antiparkinsonian, is a type of drug which is intended to treat and relieve the symptoms of Parkinson's disease (PD) or Parkinsonism. Most of these agents act by either increasing dopamine activity or reducing acetylcholine activity in the central nervous system (CNS).

Examples[edit source | edit]

- Dopaminergic Precursors:

(Preferred over other medications to prevent undesirable sympathomimetic side effects)

- - Phenylalanine
  - Tyrosine
  - L-DOPA

- Selective monoamine oxidase B inhibitors

(To prevent the metabolism of dopamine by MAO_B and hence increase its brain levels)

- - Selegiline
  - Rasagiline

- COMT inhibitors

(Preventing the metabolism of dopamine by COMT and hence increase its brain levels)

- - Entacapone
  - Tolcapone

- Dopamine receptor agonists

(Directly increase the activity of the dopamine system)

- - Apomorphine
  - Bromocriptine
  - Pramipexole
  - Ropinirole
  - Rotigotine

Anticholinergics - Antimuscarinics (e.g., Benzatropine): to prevent hyperkinesia.
- Diphenhydramine
- Dimenhydrinate
- Scopolamine
- Benztropine

References[edit source | edit]

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. アルコールおよびその他の薬物の有害な使用のスクリーニング screening for unhealthy use of alcohol and other drugs
2. リウマチ性疾患を有する男性における抗炎症剤および免疫抑制剤が性腺機能に及ぼす影響 effects of antiinflammatory and immunosuppressive drugs on gonadal function in men with rheumatic diseases
3. 統合失調症に対する薬物療法：持効性抗精神病薬注射製剤 pharmacotherapy for schizophrenia long acting injectable antipsychotic drugs
4. I群抗不整脈薬の主な副作用 major side effects of class i antiarrhythmic drugs
5. 薬物アレルギー患者へのアプローチ an approach to the patient with drug allergy

English Journal

Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson's disease and its progression: Disease and staging biomarkers and new drug targets.

de Farias CC1, Maes M2, Bonifácio KL1, Bortolasci CC1, de Souza Nogueira A1, Brinholi FF1, Matsumoto AK1, do Nascimento MA3, de Melo LB4, Nixdorf SL5, Lavado EL6, Moreira EG1, Barbosa DS7.
Neuroscience letters.Neurosci Lett.2016 Feb 6;617:66-71. doi: 10.1016/j.neulet.2016.02.011. [Epub ahead of print]
There is evidence that immune-inflammatory, stress of reactive oxygen and nitrogen species (IO&NS) processes play a role in the neurodegenerative processes observed in Parkinson's disease (PD). The aim of the present study was to investigate peripheral IO&NS biomarkers in PD. We included 56
PMID 26861200

Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence.

Collamati A1, Martone AM1, Poscia A2, Brandi V1, Celi M1, Marzetti E1, Cherubini A3, Landi F4.
Aging clinical and experimental research.Aging Clin Exp Res.2016 Feb;28(1):25-35. doi: 10.1007/s40520-015-0359-7. Epub 2015 May 1.
The use of medication with anticholinergic properties is widespread among older subjects. Many drugs of common use such as antispasmodics, bronchodilators, antiarrhythmics, antihistamines, anti-hypertensive drugs, antiparkinson agents, skeletal muscle relaxants, and psychotropic drugs have been demo
PMID 25930085

A systematic review of the statistical methods in prospective cohort studies investigating the effect of medications on cognition in older people.

Jamsen KM1, Ilomäki J2, Hilmer SN3, Jokanovic N2, Tan EC2, Bell JS4.
Research in social & administrative pharmacy : RSAP.Res Social Adm Pharm.2016 Jan-Feb;12(1):20-8. doi: 10.1016/j.sapharm.2015.04.004. Epub 2015 Apr 24.
BACKGROUND: There is increasing awareness that medications can contribute to cognitive decline. Prospective cohort studies are rich sources of clinical data. However, investigating the contribution of medications to cognitive decline is challenging because both medication exposure and cognitive impa
PMID 26003045

Japanese Journal

「目で見る薬理学」シリーズ(No.9)抗パーキンソン病薬

医療 = Japanese journal of National Medical Services : 国立医療学会誌 67(10), 424-429, 2013-10
NAID 40019848615

神経疾患治療薬の開発戦略 : パーキンソン病治療薬開発の観点から

臨床薬理 = Japanese journal of clinical pharmacology 43(2), 125-126, 2012-03-31
NAID 10030574042

薬物相互作用（１９‐パーキンソン病治療薬の薬物相互作用）

岡山医学会雑誌 122(3), 259-264, 2010
NAID 130004903186

「抗パーキンソン病薬」

　　[★]

英: antiparkinsonian drug、antiparkinsonian agent、antiparkinsonian、antiparkinson drug、antiparkinson agent
関: 抗パーキンソン病、抗パーキンソン剤

「antiparkinsonian」

　　[★]

adj.

抗パーキンソン病の

n.

抗パーキンソン病薬

関: antiparkinson agent、antiparkinson drug、antiparkinsonian agent、antiparkinsonian drug

「antiparkinsonian drug」

　　[★]

抗パーキンソン病薬、抗パーキンソン剤

関: antiparkinson agent、antiparkinson drug、antiparkinsonian、antiparkinsonian agent

「antiparkinson agent」

　　[★]

抗パーキンソン病薬

関: antiparkinson drug、antiparkinsonian、antiparkinsonian agent、antiparkinsonian drug

「antiparkinsonian agent」

　　[★]

抗パーキンソン病薬

関: antiparkinson agent、antiparkinson drug、antiparkinsonian、antiparkinsonian drug

「drug」

　　[★]

同: drugs

リンク元	「抗パーキンソン病薬」「antiparkinsonian」「antiparkinsonian drug」「antiparkinson agent」「antiparkinsonian agent」
関連記事	「drug」

匿名

検索

案内

案内

antiparkinson drug